Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.
Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.